Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00006199|
Recruitment Status : Unknown
Verified January 2004 by National Center for Research Resources (NCRR).
Recruitment status was: Recruiting
First Posted : September 11, 2000
Last Update Posted : June 24, 2005
The purpose of this clinical trial is to establish the safest doses for the combination of a farnesyl transferase inhibitor, R115777 plus topotecan in patients with advanced solid tumors, previously treated or beyond standard therapy of clinical benefit. Maximum tolerated dose, dose limiting toxicity and the activity of this combination will be assessed.
This chemotherapy regimen is a two-pronged attack at the way cancer cells replicate. R115777 is a compound that may inhibit cancer cell growth by interfering with the p21 ras oncogene, while topotecan, a topoisomerase-1 inhibitor, works on cancer cells not subject to control by the ras oncogene. Animal studies suggest that the combination may be synergistic. Another advantage is that R115777 can be taken by mouth.
|Condition or disease||Intervention/treatment||Phase|
|Cancer||Drug: R115777 (farnesyl transferase inhibitor) Drug: Topotecan||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006199
|Contact: Anita Tierney||1-212-263-2173|
|United States, New York|
|NYU Cancer Institute||Recruiting|
|New York, New York, United States, 10016|
|Contact: Anita Tierney 212-263-2173|